Morgans Corporate

Cap Raise Crucible: Canaccord leads big mining dash for cash

Roundup of 35 ASX capital raisings seeking a combined $687.5m in late August and early September, led by mining deals; Canaccord Genuity topped the broker table and three IPOs floated.

Cap Raise Crucible: Canaccord leads big mining dash for cash

Roundup tallies 35 ASX equity fundraises seeking $687.5 million, mostly miners; Canaccord Genuity led broker mandates with nine deals, while FireFly Metals' $190 million package was the period's largest.

Also The Age Business

Four ANZ startups that raised $52.1 million this week

Funding roundup covering four raises: Pay.com.au's $25 million round plus a $28 million secondary, Ruminant Biotech's Series A, Australis Scientific's Rohto-backed funding, and Paperly's $3 million round led by Tribe Global Ventures.

Also Startup Daily·Startup News (WA)

Pay.com.au hits $633 million valuation after $25 million raise

Melbourne fintech pay.com.au has banked $25 million for a US push, Morgans Corporate leading, with Wilson Asset Management, Thorney Group and Ophir participating, at a pre-money valuation of $633 million.

Smart50 success Pay.com.au raises $25 million, valuation soars to $633 million

Payment rewards platform Pay.com.au has raised $25 million led by Morgans Corporate, with $28 million of existing shares also sold, valuing the company at $633 million as it pushes into America.

Also Startup Daily·SmartCompany·Startup Daily·SmartCompany·SmartCompany·Startup Daily·SmartCompany·Dealroom·Fintech News Australia

Aura Group Appoints Advisers to Explore ASX Listing

Aura Group has hired brokers, lawyers and an auditor as it weighs floating on the ASX within two years, alongside a planned pre-listing capital raise to fuel expansion.

Sunshine Heart - $1.75 million Placement completed, $8.1 million Rights Issue announced

Sunshine Heart has completed a $1.75 million share placement and announced a rights issue, with about $4.65 million pledged so far, including cornerstone commitments from CM Capital and GBS Venture Partners.

Cephalon announces intention to offer $1.40 per share for Arana

Cephalon has announced plans to buy out Arana Therapeutics shareholders at $1.40 a share, potentially $1.45, valuing the ASX-listed target around $318 million; its independent directors back the bid unless a better one emerges.